[Resistance of multicellular spheroids to taxol in human ovarian cancer and its mechanism]. 2003

Hui Xing, and Qing-Lei Gao, and Xiao-Kui Yang, and Jing Li, and Chun Gao, and Jian-Hong Wu, and Yun-Ping Lu, and Ding Ma
Department of Obstetrics &Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei,430030, PR China.

OBJECTIVE Cytotoxic anticancer drugs are less effective in killing tumor cells grown as multicellular spheroids than monolayer cell cultures. The aim of this study was to investigate the molecular mechanism of chemoresistance. METHODS Ovarian cancer A2780, CAOV3 multicellular spheroids were obtained from three-dimensional culture. Expression of P-glycoprotein (P-gp) was determined using Western blot analysis and flow cytometry (FCM). The subcellular distribution of P-gp was also determined using laser confocal microscope. Reverse transcription-polymerase chain reaction (RT-PCR) was employed to detect the mdr1 mRNA of both monolayer cells and multicellular spheroids. Cell cycle profiles and apoptosis were also analyzed using FACS. The resistance was detected with trypan blue exclusion testing. RESULTS Compared with control cells, no expression of P-gp was detected in monolayer cells, but expression of P-gp in aggregate cells was significantly elevated(P< 0.05). The mdr1 mRNA positive nodes were confirmed by RT-PCR in the aggregate cells. The percentage of cells increased in G(0)-G(1) phase and decreased in S and G(2)-M phase significantly in spheroids cells. Spheroids cells showed higher cell viability than monolayer cells (P(A2780)=0.003, P(CAOV3)=0.015). More apoptotic cells were induced by Taxol in MCS cells than in monolayer cells. CONCLUSIONS Ovarian cancer A2780, CAOV3 multicellular spheroids cultures induced cell resistance to Taxol. High expression of P-gp was induced in ovarian multicellular spheroids and the cells were arrested in G(0)-G(1) phase.

UI MeSH Term Description Entries
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D017239 Paclitaxel A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death. 7-epi-Taxol,Anzatax,Bris Taxol,NSC-125973,Onxol,Paclitaxel, (4 alpha)-Isomer,Paxene,Praxel,Taxol,Taxol A,7 epi Taxol,NSC 125973,NSC125973,Taxol, Bris
D018874 Spheroids, Cellular Spherical, heterogeneous aggregates of proliferating, quiescent, and necrotic cells in culture that retain three-dimensional architecture and tissue-specific functions. The ability to form spheroids is a characteristic trait of CULTURED TUMOR CELLS derived from solid TUMORS. Cells from normal tissues can also form spheroids. They represent an in-vitro model for studies of the biology of both normal and malignant cells. (From Bjerkvig, Spheroid Culture in Cancer Research, 1992, p4) Multicellular Spheroids,Cellular Spheroid,Cellular Spheroids,Multicellular Spheroid,Spheroid, Cellular,Spheroid, Multicellular,Spheroids, Multicellular
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug
D020168 ATP Binding Cassette Transporter, Subfamily B, Member 1 A 170-kDa transmembrane glycoprotein from the superfamily of ATP-BINDING CASSETTE TRANSPORTERS. It serves as an ATP-dependent efflux pump for a variety of chemicals, including many ANTINEOPLASTIC AGENTS. Overexpression of this glycoprotein is associated with multidrug resistance (see DRUG RESISTANCE, MULTIPLE). ATP-Dependent Translocase ABCB1,MDR1 Protein,MDR1B Protein,Multidrug Resistance Protein 1,P-Glycoprotein,P-Glycoprotein 1,ABCB1 Protein,ATP Binding Cassette Transporter, Sub-Family B, Member 1,ATP-Binding Cassette, Sub-Family B, Member 1,CD243 Antigen,PGY-1 Protein,1, P-Glycoprotein,ABCB1, ATP-Dependent Translocase,ATP Dependent Translocase ABCB1,Antigen, CD243,P Glycoprotein,P Glycoprotein 1,PGY 1 Protein,Protein, MDR1B,Translocase ABCB1, ATP-Dependent

Related Publications

Hui Xing, and Qing-Lei Gao, and Xiao-Kui Yang, and Jing Li, and Chun Gao, and Jian-Hong Wu, and Yun-Ping Lu, and Ding Ma
January 2007, Oncology reports,
Hui Xing, and Qing-Lei Gao, and Xiao-Kui Yang, and Jing Li, and Chun Gao, and Jian-Hong Wu, and Yun-Ping Lu, and Ding Ma
August 2001, Zhonghua fu chan ke za zhi,
Hui Xing, and Qing-Lei Gao, and Xiao-Kui Yang, and Jing Li, and Chun Gao, and Jian-Hong Wu, and Yun-Ping Lu, and Ding Ma
June 1997, Cancer research,
Hui Xing, and Qing-Lei Gao, and Xiao-Kui Yang, and Jing Li, and Chun Gao, and Jian-Hong Wu, and Yun-Ping Lu, and Ding Ma
January 2019, OncoTargets and therapy,
Hui Xing, and Qing-Lei Gao, and Xiao-Kui Yang, and Jing Li, and Chun Gao, and Jian-Hong Wu, and Yun-Ping Lu, and Ding Ma
August 1979, International journal of radiation oncology, biology, physics,
Hui Xing, and Qing-Lei Gao, and Xiao-Kui Yang, and Jing Li, and Chun Gao, and Jian-Hong Wu, and Yun-Ping Lu, and Ding Ma
April 2009, Gynecologic oncology,
Hui Xing, and Qing-Lei Gao, and Xiao-Kui Yang, and Jing Li, and Chun Gao, and Jian-Hong Wu, and Yun-Ping Lu, and Ding Ma
December 1980, British journal of cancer,
Hui Xing, and Qing-Lei Gao, and Xiao-Kui Yang, and Jing Li, and Chun Gao, and Jian-Hong Wu, and Yun-Ping Lu, and Ding Ma
December 2018, Journal of nanoscience and nanotechnology,
Hui Xing, and Qing-Lei Gao, and Xiao-Kui Yang, and Jing Li, and Chun Gao, and Jian-Hong Wu, and Yun-Ping Lu, and Ding Ma
January 1997, Anti-cancer drugs,
Hui Xing, and Qing-Lei Gao, and Xiao-Kui Yang, and Jing Li, and Chun Gao, and Jian-Hong Wu, and Yun-Ping Lu, and Ding Ma
January 1995, European journal of cancer (Oxford, England : 1990),
Copied contents to your clipboard!